Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:


Last Updated: January 31, 2023

Details for Patent: 7,612,087

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,612,087 protect, and when does it expire?

Patent 7,612,087 protects AVYCAZ and is included in one NDA.

This patent has sixty-seven patent family members in forty-four countries.

Summary for Patent: 7,612,087
Title:Heterocyclic compounds as inhibitors of beta-lactamases
Abstract: This invention discloses and claims methods for inhibiting bacterial .beta.-lactamases and treating bacterial infections by inhibiting bacterial .beta.-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a .beta.-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a .beta.-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. ##STR00001##
Inventor(s): Aszodi; Jozsef (Tucson, AZ), Fromentin; Claude (Paris, FR), Lampilas; Maxime (Saint Cloud, FR), Rowlands; David Alan (Poissy, FR)
Assignee: Novexel (Romainville, FR)
Application Number:10/898,754
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,612,087

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,612,087

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 00951Jan 28, 2002

International Family Members for US Patent 7,612,087

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038234 See Plans and Pricing
Argentina 100790 See Plans and Pricing
Austria 484281 See Plans and Pricing
Australia 2003214335 See Plans and Pricing
Brazil 0307267 See Plans and Pricing
Brazil 122015020406 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.